• Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med [Internet]. 2020 Sep; Available from: https://doi.org/10.1056/NEJMoa2027071. This reference is of importance because this phase III trial demonstrated a significant disease-free survival benefit of osimertinib over placebo in resected EGFR-mutated NSCLC, consequently leading to the approval of adjuvant osimertinib.

•• Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet. 2021;398(10308):1344–57 This reference is of outstanding importance because this is the first phase III trial to demonstrate a significant disease-free survival benefit of adjuvant immunotherapy in resected NSCLC, consequently leading to the approval of adjuvant atezolizumab.

Article  CAS  Google Scholar 

Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for advanced non–small cell lung cancer: a decade of progress. Am Soc Clin Oncol Educ Book. 2021;41:e105–27.

Article  Google Scholar 

• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50 This reference is of importance because this phase III trial demonstrated a significant overall survival benefit of consolidation durvalumab post-chemoradiation in unresectable stage 3 NSCLC, consequently introducing immunotherapy to the curative setting.

Article  CAS  PubMed  Google Scholar 

Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, et al. Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. J Thorac Oncol. 2021;16(7):1099–117.

Article  CAS  PubMed  Google Scholar 

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul;26(21):3552–9.

•• O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–86 This reference is of outstanding importance because this is the second phase III trial evaluating the benefit of adjuvant immunotherapy in resected NSCLC, with important observations distinct from IMpower010.

Article  PubMed  Google Scholar 

Felip E, Altorki N, Vallieres E, et al. PL03.09 IMpower010: overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC. In: In 2022 World Conference on Lung Cancer in Vienna. Austria; 2022.

Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–30.

Article  CAS  PubMed  Google Scholar 

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, et al. Tumor mutation burden as a biomarker in resected non–small-cell lung cancer. J Clin Oncol. 2018;36(30):2995–3006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiao XD, He X, Qin BD, Liu K, Wu Y, Liu J, et al. The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. J Thorac Dis. 2019;11(11):4507–15.

Article  PubMed  PubMed Central  Google Scholar 

Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022;17(3):399–410.

Article  CAS  PubMed  Google Scholar 

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40.

Article  PubMed  PubMed Central  Google Scholar 

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593.

Article  PubMed  PubMed Central  Google Scholar 

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, et al. Relationship between overall survival and response or progression-free survival in advanced non–small cell lung cancer patients treated with anti–PD-1/PD-L1 antibodies. J Thorac Oncol. 2016;11(11):1927–39.

Article  PubMed  PubMed Central  Google Scholar 

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol. 2013/05/14 ed. 2013;14(7):619–26.

Article  PubMed  PubMed Central  Google Scholar 

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–48.

Article  CAS  PubMed  Google Scholar 

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713–22.

Article  CAS  PubMed  Google Scholar 

Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer—a meta-analysis. J Thorac Oncol. 2017;12(2):403–7.

Article  PubMed  Google Scholar 

Dotsu Y, Horiike A, Yoshizawa T, Sonoda T, Koyama J, Saiki M, et al. Programmed death-ligand 1 expression after progressive disease with EGFR-TKI and efficacy of anti-programmed death-1 antibody in non-small cell lung cancer(NSCLC) harboring EGFR mutation. J Clin Oncol. 2018;36(15_suppl):e21232–2.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, et al. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study. Lung Cancer. 2020;147:137–42.

Article  PubMed  Google Scholar 

Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4):S115.

Article  Google Scholar 

Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, et al. A phase II Study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13(8):1138–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013;24(8):2080–7.

Article  CAS  PubMed  Google Scholar 

Sun D, Zhu Y, Zhu J, Tao J, Wei X, Wo Y, et al. Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC. Mol Med. 2020;26(1):66.

Article  PubMed  PubMed Central  Google Scholar 

He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. 2021;59(5):90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med [Internet]. 2022 [cited 2022 Apr 19]; Available from: 10.1056/NEJMoa2202170. This reference is of outstanding importance because this phase III trial demonstrated a significant improvement in both pathological complete response and event-free survival with the addition of nivolumab to neoadjuvant chemotherapy, thereby changing the paradigm of treatment in resectable lung cancer.

Saw SPL, Ong BH, Chua KLM, Takano A, Tan DSW. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol. 2021;22(11):e501–16.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med [Internet]. 2018 Dec 5 [cited 2019 Jan 13]; Available from: https://doi.org/10.1056/NEJMoa1814017

Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non–small-cell lung cancer treated with curative intent. J Clin Oncol. 2022;40(6):567–75.

Article  CAS  PubMed  Google Scholar 

• Zhou C, Das Thakur M, Srivastava MK, Zou W, Xu H, Ballinger M, et al. 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Ann Oncol. 2021;32:S1374 This reference is of importance because this post-hoc analysis of the landmark IMpower010 trial highlights the value of biomarkers such as ctDNA levels in predicting survival outcomes, but also illustrates the challenges in measuring minimal residual disease post-surgery.

Article  Google Scholar 

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394 LP–1403.

Article  Google Scholar 

Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res [Internet]. 2021; Available from: https://clincancerres.aacrjournals.org/content/early/2021/06/22/1078-0432.CCR-21-0410

Li C, He Q, Liang H, Cheng B, Li J, Xiong S, et al. Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer: a meta-analysis. Front Oncol. 2020;10:290.

Article  PubMed  PubMed Central  Google Scholar